FindTrial
Sign In

A study on exploring machine learning based radiomics biomarkers and prognostic model for HCC treated with TACE plus PD-1/PD-L1 inhibitors and antiangiogenic therapies

A study on exploring machine learning based radiomics biomarkers and prognostic model for HCC treated with TACE plus PD-1/PD-L1 inhibitors and antiangiogenic therapies

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200061765
Enrollment
Unknown
Registered
2022-07-02
Start date
2022-06-18
Completion date
Unknown
Last updated
2023-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

N/A:N/A

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. confirmed diagnosis of HCC; 2. intermediate stage according to BCLC staging system; 3. ECOG < 2; 4. expected life of more than 12 weeks; 5. preserved liver and renal functions.

Exclusion criteria

Exclusion criteria: 1. contraindication to TACE or ICIs or anti-VEGF drugs; 2. treatment history of more than two sessions of TACE and HCC-related systemic therapies; 3. other kinds of malignant tumors; 4. serious allergy to iodine contrast agent or previous history of contrast agent-related anaphylactic shock.

Countries

China

Contacts

Public ContactBinYan Zhong

The First Affiliated Hospital of Soochow University

byzhongir@sina.com+86 15850522044

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026